***A close-up of a logo

Description automatically generatedSemiannual Meeting***

*Friday, May 31, 2024 7:30 am-12:00 pm Central Time*

*Hyatt Centric Chicago Magnificent Mile (Grand Ballroom)*

|  |  |  |
| --- | --- | --- |
| **7:30 am** | **Breakfast** | |
| **8:00-8:20** | **SARC Clinical & Science Initiatives** | |
| **Upcoming events & collaborative opportunities** | | **Chappie Conrad MD** (SARC Board Chair; UT Houston)  **Jonathan Fletcher MD** (SARC CSO; Harvard U.)  **Scott Okuno MD** (SARC CMO; Mayo Clinic)  **Steven Young** (SARC President & CEO) |
| **8:20-9:50** | **Targeting DDR and Genomic Integrity in Sarcoma** | |
| **Introductions by Moderators** | | **Jonathan Fletcher MD**  **Rebecca Gladdy MD PhD** (U. of Toronto) |
| **Manipulating DDR protein localization: Tx strategies** | | **David Loeb MD PhD** (Albert Einstein College of Medicine) |
| **Precision oncology in osteosarcoma** | | **Katie Janeway MD** (Dana-Farber Cancer Institute) |
| **SARC032: RT/I-O for extremity sarcoma – What have we learned?** | | **David Kirsch MD PhD** (Princess Margaret Cancer Centre, UHN) |
| **Discussion** | |  |
| **9:50-10:20** | **Break (30 minutes)** | |
| **10:20-11:20** | **SARC028: Lessons Learned/Paths Forward** | |
| **Introductions**  **Moderator/Coordinator** | | **Scott Okuno MD**  **Sandra D’Angelo MD** (Memorial Sloan Kettering Cancer Institute) |
| **SARC 028: Development and Results** | | **Melissa “Missy” Burgess MD** (U. of Pittsburgh Medical Center) |
| **TLS as a Predictor biomarker**  **Proponents:**  **Against:** | | **Florent Petitprez PhD** (U. of Edinburgh)&  **Emily Z. Keung MD** (MD Anderson Cancer Center)  **Breelyn Wilky MD** (U. of Colorado) |
| **Discussion** | |  |
| **11:20-11:45** | **Career Awardee Presentation** | |
| **Androgen receptor targeting in DSRCT** | | **Danh Truong PhD** (MD Anderson Cancer Center) |
| **11:45-12:00** | **SARC-Sponsored Clinical Trials** | **Presenter (bolded)** |
| **Introductions** | | **Scott Okuno MD** |
| **SARC037 Phase I/II Trabectedin in Ewing Sarcoma in Combination with Irinotecan & 18F-FLT Imaging** | | **Patrick Grohar MD PhD** (Children’s Hospital of Philadelphia) |
| **SARC041 Phase III Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS** | | **Mark Dickson MD** (Memorial Sloan Kettering Cancer Institute) |
| **SARC044 Phase II Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST who Progressed on Sunitinib Monotherapy** | | **Candace Haddox MD** (Dana-Farber Cancer Institute) |
| **12:00 noon Closing Comments & Adjourn** | |  |